Patents by Inventor Müge Serhatli

Müge Serhatli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRODUCTION OF PROTECTIVE LOZENGE/CHEWABLE TABLET AGAINST SARS-COV-2 VIRUS
    Publication number: 20250090620
    Abstract: Clean version of Abstract A mixture consisting of extracts of green tea, bilberry, pomegranate peel, and black poplar Propolis is produced. Upon revealing the surprising efficacy of the mixture against SARS-CoV-2 virus, the mixture was put into lozenge/chewable tablet form and its activity against the SARS-CoV-2 virus was demonstrated. The invention was developed in the form of a throat lozenge/chewable tablet in order to provide a protective effect around the mouth and throat, which is the first point of entry of the SARS-CoV-2 virus. The effectiveness of the mixture against SARS-CoV-2 virus was tested on VERO E6 cells by in vitro methods. In the experiments lasting 160 hours, the mixture neutralizes the virus by 112% (61% cell viability) at 110 ?g/mL concentration and by 35% (82% cell viability) at 70 ?g/mL concentration. The combination of herbal extracts with Propolis extract were synergically more effective (?7-fold higher) than that of individual extract.
    Type: Application
    Filed: January 10, 2023
    Publication date: March 20, 2025
    Applicant: TUBITAK
    Inventors: Cesarettin ALASALVAR, Ebru PELVAN PELITLI, Oznur KARAOGLU, Bulent KARADENIZ, Ilknur DEMIRTAS, Müge SERHATLI, Erdem YESILADA
  • Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (VEGFR—2/KDR)
    Patent number: 9193792
    Abstract: Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: November 24, 2015
    Assignee: TUBITAK
    Inventors: Berrin Erda{hacek over (g)}, Bertan Koray Balcio{hacek over (g)}lu, Aylin Ozdemir Bahadir, Aydin Bahar, Kemal Baysal, Müge Serhatli, Omer Kaçar, Türker Kiliç, Emel Akgün, Abdulkadir Özkan
  • RECOMBINANT ANTIBODY STRUCTURES BINDING TO AND BLOCKING THE ACTIVITY OF VASCULAR ENDOTHELIAL GROWTH FACTOR 2 (VEGFR- 2/KDR)
    Publication number: 20140199301
    Abstract: Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors.
    Type: Application
    Filed: July 7, 2010
    Publication date: July 17, 2014
    Applicant: TUBITAK
    Inventors: Berrin Erdag, Bertan Koray Balcioglu, Aylin Ozdemir Bahadir, Aydin Bahar, Kemal Baysal, Müge Serhatli, Omer Kaçar, Turker Kiliç, Emel Akgün, Abdulkadir Özkan